189 related articles for article (PubMed ID: 10897159)
1. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.
Cramer JA; Arrigo C; Van Hammée G; Gauer LJ; Cereghino JJ
Epilepsia; 2000 Jul; 41(7):868-74. PubMed ID: 10897159
[TBL] [Abstract][Full Text] [Related]
2. Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam.
Cramer JA; Arrigo C; Van Hammée G; Bromfield EB
Epilepsy Res; 2000 Aug; 41(1):29-38. PubMed ID: 10924866
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
Ben-Menachem E; Falter U
Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
[TBL] [Abstract][Full Text] [Related]
4. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.
Chaisewikul R; Privitera MD; Hutton JL; Marson AG
Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.
Tsai JJ; Yen DJ; Hsih MS; Chen SS; Hiersemenzel R; Edrich P; Lai CW
Epilepsia; 2006 Jan; 47(1):72-81. PubMed ID: 16417534
[TBL] [Abstract][Full Text] [Related]
7. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
[TBL] [Abstract][Full Text] [Related]
8. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
9. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
10. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures.
Zhou B; Zhang Q; Tian L; Xiao J; Stefan H; Zhou D
Epilepsy Behav; 2008 Feb; 12(2):305-10. PubMed ID: 18024209
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
Glauser TA; Pellock JM; Bebin EM; Fountain NB; Ritter FJ; Jensen CM; Shields WD
Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
13. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
14. Rapid onset of action of levetiracetam in refractory epilepsy patients.
French J; Arrigo C
Epilepsia; 2005 Feb; 46(2):324-6. PubMed ID: 15679515
[TBL] [Abstract][Full Text] [Related]
15. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
Kinirons P; McCarthy M; Doherty CP; Delanty N
Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211
[TBL] [Abstract][Full Text] [Related]
16. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
17. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
[TBL] [Abstract][Full Text] [Related]
18. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam.
Cramer JA; Van Hammée G;
Epilepsy Behav; 2003 Apr; 4(2):118-23. PubMed ID: 12697135
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.
Perry MS; Benatar M
Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
